1. Combination of pioglitazone and dendritic cell to optimize efficacy of immune cell therapy in CT26 tumor models

Samaneh Tokhanbigli , Helia Alavifard , Hamid Asadzadeh Aghdaei, Mohammad Reza Zali, Kaveh Baghaei*

Bioimpacts. 2023;13(4): 333-346. doi: 10.34172/bi.2022.24209

PMCID: PMC10460770 PMID: 37645031 Scopus ID: 85154024997

Article

PDF

Full Text

XML

Cited By:

Combining LY6E loaded DC therapy with pioglitazone improved the DC therapy effect for colorectal cancer treatment. LY6E pulsed DCs excites the CD8 positive immune responses against colorectal models. Pioglitazone inhibits IL-6 axis and formation of CRC cell lines proliferation through IL-6/STAT3 by influencing the immunosuppressive feature of the tumor microenvironment.

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons